DEF: Apellis Pharmaceuticals Aims for Continued Growth with EMPAVELI and SYFOVRE, Announces 2025 Annual Meeting

Apellis Pharmaceuticals outlines its strategic achievements in 2024 and plans for 2025, focusing on expanding the market reach of EMPAVELI and SYFOVRE and advancing its pipeline.

Summary

• Apellis Pharmaceuticals is focused on developing and commercializing therapies through complement system inhibition.
• In 2024, the company generated $781.4 million in total revenue, a 97% increase year-over-year.
• EMPAVELI and SYFOVRE generated $710 million in U.S. net product revenue in 2024.
• A credit facility with Sixth Street provided up to $475 million, eliminating $366 million in cash payments through 2027.
• SYFOVRE injections reached over 510,000 doses by year-end 2024.
• Phase 3 VALIANT study showed positive results for EMPAVELI in treating C3G and IC-MPGN.
• The FDA accepted the sNDA for EMPAVELI with a PDUFA target action date of July 28, 2025.
• The company plans to initiate Phase 3 clinical trials for EMPAVELI in FSGS and DGF in the second half of 2025.
• Keli Walbert and Craig Wheeler joined the Board of Directors.
• The Annual Meeting of Stockholders is scheduled for June 3, 2025.
• Stockholders will vote on the election of directors, ratification of the accounting firm, and executive compensation.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for Apellis Pharmaceuticals, highlighting significant revenue growth, successful clinical trial results, and strategic advancements. The tone is optimistic and confident, reflecting the company's strong performance and future potential.

Positives

• Significant revenue growth of 97% year-over-year, reaching $781.4 million in 2024.
• Market leadership of SYFOVRE in the GA treatment space, with over 510,000 doses administered.
• Positive Phase 3 VALIANT study results for EMPAVELI in C3G and IC-MPGN.
• FDA acceptance and Priority Review designation of the sNDA for EMPAVELI.
• Strengthened financial position with a $475 million credit facility and $411 million in cash reserves.
• Expansion of the Board of Directors with the addition of Keli Walbert and Craig Wheeler.
• Marketing approval for SYFOVRE in Australia in January 2025.
• Positive Phase 1 results with APL-3007 in healthy volunteers.

Future Outlook

Apellis expects 2025 to be another important year with the expected approval and launch of EMPAVELI in two additional indications and the initiation of a Phase 2 study with SYFOVRE and APL-3007.

Management Comments

• At Apellis, we are driven by a relentless commitment to creating value for both patients and shareholders alike.
• We brought EMPAVELI and SYFOVRE to the market, two blockbuster potential products that are making a meaningful difference for patients, advanced our robust pipeline of clinical and pre-clinical programs and fortified our financial position.
• I am proud of our team and all we have accomplished together.
• With the expected approval and launch of EMPAVELI in two additional indications, we expect that 2025 will be another important year for Apellis.
• Your gracious, unwavering support and confidence in Apellis will enable us to continue pushing the boundaries of scientific discovery and redefining the future of healthcare.

Industry Context

Apellis operates in the competitive biopharmaceutical industry, focusing on complement system inhibition. The company competes with larger, more established companies and smaller private companies for executive talent and market share. The success of EMPAVELI and SYFOVRE is crucial for Apellis to maintain its position and fund further development.

Comparison to Industry Standards

• Apellis competes with companies like ACADIA Pharmaceuticals, Exelixis, Inc., and Sarepta Therapeutics for market share and executive talent.
• The company's revenue growth of 97% year-over-year is a strong indicator of its competitive position.
• The success of SYFOVRE in the GA treatment market positions Apellis as a leader in ophthalmology.
• The positive results from the Phase 3 VALIANT study for EMPAVELI in C3G and IC-MPGN could establish it as a standard of care for these diseases.
• The company's pipeline development, including the gene-editing approach with Beam Therapeutics, demonstrates its commitment to innovation.

Next Steps

• Launch EMPAVELI for C3G and IC-MPGN in the third quarter of 2025, pending FDA approval.
• Initiate Phase 3 clinical trials for EMPAVELI in FSGS and DGF in the second half of 2025.
• Initiate a Phase 2 study with SYFOVRE and APL-3007 in the second quarter

Key Dates

Keywords

SYFOVRE, EMPAVELI, geographic atrophy, C3 glomerulopathy, IC-MPGN, complement cascade, ophthalmology, nephrology, Apellis Pharmaceuticals, clinical trials, revenue, FDA, PDUFA, proxy statement, annual meeting